Sleepiness and Depression in Parkinson's Disease Patients Treated with Ropinirole and Levodopa
Journal of Movement Disorders
; : 123-129, 2017.
Article
in En
| WPRIM
| ID: wpr-90986
Responsible library:
WPRO
ABSTRACT
OBJECTIVE: We aimed to investigate the effect of ropinirole on excessive daytime sleepiness (EDS) and depression in Parkinson’s disease (PD) with a large population. METHODS: We conducted a cross-sectional observational study at nine hospitals in Korea between April 24, 2013, and April 22, 2015. We analyzed the demographic and clinical features, other medical history, history of antiparkinsonian medication within 6 months, Hoehn and Yahr stage (HY stage), Unified Parkinson’s Disease Rating Scale (UPDRS) part II and III, Epworth Sleepiness Scale (ESS), and 30-item Geriatric Depression Scale (GDS-30). RESULTS: Four-hundred-thirteen patients with PD (mean age: 65.2 ± 9.0 years; men: 227 patients) were analyzed. Multivariate logistic regression analysis showed that age at examination, UPDRS II, and GDS-30 were independent risk factors for EDS and that sex, UPDRS II, and ESS were independent risk factors for depression. CONCLUSION: Our large group study did not find any significant associations of ropinirole with EDS and depression in Korean PD patients.
Key words
Full text:
1
Database:
WPRIM
Main subject:
Parkinson Disease
/
Levodopa
/
Logistic Models
/
Risk Factors
/
Depression
/
Observational Study
/
Korea
Type of study:
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Humans
/
Male
Country/Region as subject:
Asia
Language:
En
Journal:
Journal of Movement Disorders
Year:
2017
Document type:
Article